Evidence map›Paper›PMID 37108680›Full record

ArticleInternational journal of molecular sciences2023

Targeted Large-Volume Lymphocyte Removal Using Magnetic Nanoparticles in Blood Samples of Patients with Chronic Lymphocytic Leukemia: A Proof-of-Concept Study.

Stefanie Janker, Simon Doswald, Roman R Schimmer, Urs Schanz, Wendelin J Stark, Martin Schläpfer, Beatrice Beck-Schimmer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Stefanie JankerInstitute of Anesthesiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Simon DoswaldInstitute for Chemical and Bioengineering, ETH, 8093 Zurich, Switzerland.
Roman R SchimmerInstitute of Physiology, University of Zurich, 8057 Zurich, Switzerland.
Urs SchanzDepartment of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Wendelin J StarkInstitute for Chemical and Bioengineering, ETH, 8093 Zurich, Switzerland.
Martin SchläpferInstitute of Anesthesiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0003-4288-7124
Beatrice Beck-SchimmerInstitute of Anesthesiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0002-0648-6115
University of Zurich · CHInstitute for Biomedical Engineering · CH

Funding

Swiss National Science Foundation 320030_160283Swiss National Science Foundation 406440_131268
6 · The paper itself

Abstract

In the past, our research group was able to successfully remove circulating tumor cells with magnetic nanoparticles. While these cancer cells are typically present in low numbers, we hypothesized that magnetic nanoparticles, besides catching single cells, are also capable of eliminating a large number of tumor cells from the blood ex vivo. This approach was tested in a small pilot study in blood samples of patients suffering from chronic lymphocytic leukemia (CLL), a mature B-cell neoplasm. Cluster of differentiation (CD) 52 is a ubiquitously expressed surface antigen on mature lymphocytes. Alemtuzumab (MabCampath

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellMagnetite NanoparticlesAlemtuzumabAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntigens, CDAntigens, NeoplasmCarbonCD52 AntigenGlycoproteinsHumansLymphocytesPilot ProjectsAlemtuzumabAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntigens, CDAntigens, NeoplasmCarbonCD52 AntigenGlycoproteinsMagnetite Nanoparticlesblood purificationnanoparticlesspecific cell removaltumor cell elimination

Identifiers

PMID37108680
PMCPMC10139131
OpenAlexW4366528988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.